Rybelsus 3mg Tablet

Rybelsus 3mg Tablet is the world's first oral GLP-1 receptor agonist, containing Semaglutide 3mg, manufactured by Novo Nordisk Pharma India Ltd. It is indicated as an adjunct to diet and exercise for the management of blood glucose in adults with Type 2 Diabetes Mellitus (T2DM). The 3mg dose is specifically the starting dose used during the first 30 days of treatment to improve gastrointestinal tolerability before stepping up to the therapeutic 7mg or 14mg doses. Available from Shabbir Medical Hall at the best price in India, this genuine prescription tablet is available online with fast delivery nationwide.

BENEFITS: Rybelsus 3mg is part of the semaglutide GLP-1 receptor agonist class — the most clinically advanced category of oral antidiabetic therapy available today. Semaglutide lowers blood glucose through a multi-targeted mechanism: stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and reducing appetite and food intake through central hypothalamic pathways. Clinical data from the PIONEER trials demonstrate significant HbA1c reductions with semaglutide 7mg and 14mg, along with meaningful body weight reduction — a dual benefit highly relevant for overweight T2DM patients. Rybelsus offers the convenience of a once-daily oral tablet — eliminating the need for daily injections required by injectable GLP-1 receptor agonists such as liraglutide or injectable semaglutide (Ozempic).

USAGE OVERVIEW: Rybelsus 3mg is taken ONCE DAILY on an empty stomach, upon waking, with no more than 120 mL (half a glass) of plain water only — at least 30 minutes before the first food, drink (other than water), or other oral medications of the day. After 30 days on 3mg, the dose is increased to 7mg once daily; after a further 30 days, if additional glycaemic control is needed, the dose is increased to 14mg once daily.

SAFETY OVERVIEW: Most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and reduced appetite — typically occurring at treatment initiation and improving over time. This medicine is NOT recommended for Type 1 Diabetes, diabetic ketoacidosis, severe renal impairment, or during pregnancy.

Uses / Indications:

PRIMARY INDICATION:
• Type 2 Diabetes Mellitus (T2DM) in adults: as adjunct to diet and exercise to improve glycaemic control
• Monotherapy: when metformin is not tolerated or is contraindicated
• Add-on therapy: in combination with other oral antidiabetics (metformin, SGLT2 inhibitors, sulfonylureas, thiazolidinediones) or basal insulin when existing therapy does not provide adequate blood glucose control

DOSE-SPECIFIC ROLE OF RYBELSUS 3MG:
• Rybelsus 3mg is the INITIATION DOSE ONLY — used for the first 30 days to improve gastrointestinal tolerability
• It is NOT a therapeutic (blood-sugar lowering) dose — clinical trials demonstrated minimal HbA1c lowering at 3mg
• After 30 days: step up to Rybelsus 7mg once daily (therapeutic dose)
• After a further 30 days at 7mg: if additional control needed, step up to Rybelsus 14mg once daily (maximum dose)

ADDITIONAL INVESTIGATIONAL / OFF-LABEL CONTEXT:
• Cardiovascular risk reduction: injectable semaglutide (Ozempic) has established CV benefit in T2DM with CVD; oral semaglutide PIONEER 6 trial showed non-inferiority for CV outcomes
• Obesity management: injectable semaglutide 2.4mg (Wegovy) is approved for obesity — Rybelsus is NOT approved for obesity alone
• NOT indicated for Type 1 Diabetes, LADA, or DKA

WHO IS RYBELSUS FOR?
• Adults with T2DM requiring improved glycaemic control with or without other oral antidiabetics
• Patients who prefer an oral formulation over injectable GLP-1 therapy
• Overweight/obese T2DM patients who may benefit from semaglutide's weight-lowering effect

Interactions / Warnings:

PANCREATITIS WARNING: Rybelsus should be used with caution in patients with a history of pancreatitis. DISCONTINUE immediately if acute pancreatitis is suspected (severe abdominal pain, elevated lipase/amylase). Do NOT restart without physician evaluation confirming alternative aetiology.

MEDULLARY THYROID CARCINOMA (MTC) / MEN2 WARNING: CONTRAINDICATED in patients with personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Animal studies (rodents) showed dose-dependent thyroid C-cell tumours with GLP-1 receptor agonists — relevance to humans is uncertain but a precautionary contraindication exists. Advise patients to report neck masses, dysphagia, dysphonia, or persistent hoarseness.

DIABETIC RETINOPATHY: Rapid improvement in blood glucose may transiently worsen diabetic retinopathy complications. Baseline ophthalmological examination and regular follow-up recommended in patients with known retinopathy.

RENAL IMPAIRMENT: No dose adjustment required for mild-moderate renal impairment. Severe renal impairment (eGFR <15 mL/min/1.73m²): limited data — use with caution; monitor renal function. Dehydration from GI side effects can precipitate acute kidney injury — ensure adequate hydration.

HEPATIC IMPAIRMENT: No dose adjustment required for mild-severe hepatic impairment. Use with caution in severe hepatic impairment — limited clinical experience.

HEART RATE: Semaglutide may increase heart rate by 2–3 bpm on average — monitor in patients with known cardiac arrhythmias or tachycardia.

NOT FOR TYPE 1 DIABETES: Rybelsus is NOT indicated for Type 1 Diabetes, LADA (Latent Autoimmune Diabetes in Adults), or diabetic ketoacidosis. It does NOT replace insulin in insulin-dependent patients.

Pregnancy interaction:

PREGNANCY SAFETY:
• Rybelsus (Semaglutide) is CONTRAINDICATED in pregnancy
• Animal reproduction studies showed embryo-foetal toxicity (skeletal malformations, growth retardation) at doses overlapping clinical exposure — not safe
• GLP-1 receptor agonists may affect foetal organogenesis, particularly in the first trimester
• WOMEN OF CHILDBEARING POTENTIAL: use effective contraception during Rybelsus therapy
• STOP Rybelsus at least 2 months before a planned pregnancy — semaglutide has a long half-life (~1 week) and takes approximately 5 weeks to wash out; additional safety margin recommended
• If pregnancy is detected during treatment: STOP immediately and consult endocrinologist/obstetrician for safe alternative antidiabetic management
• During pregnancy, insulin remains the preferred antidiabetic therapy for T2DM

BREASTFEEDING:
• It is unknown whether semaglutide is excreted in human milk
• Based on animal data and the drug's properties, excretion into breast milk is considered possible
• A decision must be made whether to discontinue breastfeeding or discontinue Rybelsus — consult endocrinologist

FERTILITY:
• Animal studies showed no effects on fertility
• No human data on fertility effects — advise patients to plan pregnancy carefully with their diabetologist

Expert advice:

PHARMACIST BEST PRACTICES:

1. THE 30-MINUTE FASTING RULE IS NON-NEGOTIABLE — AND OFTEN MISUNDERSTOOD:
• Rybelsus 3mg must be taken first thing upon waking, with NO MORE THAN 120 mL of plain water ONLY. No tea, no coffee, no milk, no juice — not even a sip. No other medications. You must then fast for AT LEAST 30 MINUTES before eating, drinking anything else, or taking any other oral medicine. Clinical studies show that taking Rybelsus with a small meal (250 kcal) reduces semaglutide AUC by ~40%, and drinking more than 120 mL of water reduces absorption by ~30%. This is the most commonly violated rule and the most common reason patients see reduced efficacy from Rybelsus.

2. RYBELSUS 3MG IS A STARTER DOSE — NOT THE TREATMENT DOSE:
• Many patients mistakenly believe that if 3mg is not working, the medicine is ineffective. Rybelsus 3mg is not expected to lower blood sugar — it is used ONLY for the first 30 days to allow the body to adjust to semaglutide and reduce gastrointestinal side effects. After 30 days, your diabetologist will increase the dose to 7mg (the first therapeutic dose). Continue taking 3mg as prescribed during this period — it is building tolerance, not treating T2DM directly.

3. MANAGE NAUSEA PROACTIVELY — IT PEAKS EARLY AND THEN IMPROVES:
• Nausea is the most commonly reported side effect of Rybelsus — especially in the first 4–8 weeks as the dose is being escalated. Practical strategies to manage GI side effects: eat smaller, more frequent meals; avoid high-fat, fried, spicy foods; avoid alcohol; keep well hydrated between meals; and eat slowly. If nausea is severe and you are unable to drink fluids, seek medical attention — dehydration can affect kidney function.

4. WATCH FOR PANCREATITIS SYMPTOMS AND SEEK URGENT HELP:
• Any severe, persistent abdominal pain — especially radiating to the back — could indicate acute pancreatitis, a rare but serious complication of GLP-1 receptor agonist therapy. DO NOT wait for a routine appointment. Go to your nearest emergency department immediately, inform the doctor you are on semaglutide (Rybelsus), and STOP the tablet until further assessment.

5. IF YOU TAKE INSULIN OR SULFONYLUREAS, INCREASE YOUR GLUCOSE MONITORING:
• Adding Rybelsus to a sulfonylurea or insulin regimen significantly increases the risk of hypoglycaemia (low blood sugar). Your diabetologist may need to reduce your sulfonylurea or insulin dose when Rybelsus is initiated. Learn to recognise hypoglycaemia symptoms: sweating, shakiness, palpitations, confusion, blurred vision — and always carry a fast-acting glucose source (glucose tablets or juice).

MONITORING ADVICE:
• Blood glucose (fasting and postprandial): Frequency as directed — typically daily or every 2–3 days for non-insulin users; more frequently when adding to insulin/sulfonylurea
• HbA1c: Every 3 months initially; every 6 months once stable (target <7% for most patients)
• Body weight: Monthly — track the weight loss benefit
• Renal function (serum creatinine, eGFR): Baseline; annually or if GI side effects cause dehydration
• Liver Function Tests: Baseline; periodically as indicated
• Lipid profile: Annually — semaglutide may modestly improve lipid profile
• Serum lipase/amylase: If abdominal symptoms develop — pancreatitis monitoring
• Ophthalmological examination: Baseline and annually in patients with existing diabetic retinopathy
• Thyroid examination: Be alert to any neck swelling, hoarseness, or dysphagia — rare MTC concern

COMPLIANCE TIPS:
• Set a daily morning alarm labelled 'Rybelsus — plain water only, no food for 30 min'
• Keep the bottle on your bedside table so you remember to take it BEFORE getting up
• Store the bottle tightly closed in original packaging — semaglutide is moisture-sensitive
• Do NOT transfer tablets to pill organisers — keep in original bottle
• Do NOT crush, split, or chew tablets — the SNAC absorption technology requires an intact tablet

SAFETY TIPS:
• Women planning pregnancy: stop Rybelsus at least 2 months before planned conception and switch to insulin
• Sick-day rules: if vomiting or diarrhoea prevent food intake — hold the Rybelsus dose and contact your diabetologist for glucose management advice
• Before any surgery: inform your surgeon and anaesthetist you are on Rybelsus — gastric emptying delay is relevant to anaesthesia fasting protocols
• Alcohol: moderate intake may be acceptable, but excess alcohol increases hypoglycaemia risk and GI side effects

Side Effects:

VERY COMMON SIDE EFFECTS (>1 in 10 patients) — mostly at initiation, improve over time:
• Nausea — most frequently reported; typically peaks in first 4–8 weeks then subsides
• Diarrhoea, vomiting, abdominal pain, constipation
• Decreased appetite — contributes to the weight loss benefit
• Dyspepsia, abdominal distension, eructation (belching), flatulence

COMMON SIDE EFFECTS (1 in 10 to 1 in 100 patients):
• Hypoglycaemia (low blood sugar): LOW RISK when used as monotherapy; significant risk when combined with sulfonylureas or insulin — dose reduction of the sulfonylurea/insulin may be required
• Fatigue, dizziness
• Elevated lipase and amylase (pancreatic enzyme levels) — asymptomatic in most cases
• Gallstones (cholelithiasis) — GLP-1 receptor agonists are associated with increased gallstone formation

SERIOUS SIDE EFFECTS (uncommon/rare — seek immediate medical attention):
• Acute Pancreatitis: severe, persistent abdominal pain radiating to the back, vomiting — STOP Rybelsus immediately and seek emergency care; do NOT restart without physician evaluation
• Diabetic Retinopathy Complications: rapid improvement in blood glucose control can transiently worsen diabetic retinopathy — regular eye examinations recommended in patients with pre-existing retinopathy
• Acute Kidney Injury: secondary to severe dehydration from persistent vomiting/diarrhoea — stay well hydrated; seek medical attention if unable to keep fluids down
• Severe Hypersensitivity / Anaphylaxis: rash, facial/throat swelling, difficulty breathing — SEEK EMERGENCY HELP
• Medullary Thyroid Carcinoma (theoretical risk based on rodent studies — not confirmed in humans; contraindicated in patients with personal/family history of MTC or MEN2)

How to use:

DOSAGE SCHEDULE (always as directed by your diabetologist/endocrinologist):

STEP-UP DOSING PROTOCOL:
• Days 1–30: Rybelsus 3mg once daily (initiation / tolerability phase — NOT a glycaemic target dose)
• Days 31–60: Rybelsus 7mg once daily (first therapeutic dose; most patients achieve glycaemic goals here)
• Days 61+: Rybelsus 14mg once daily (maximum dose; for patients needing additional HbA1c reduction)

CRITICAL ADMINISTRATION RULES — MUST BE FOLLOWED EXACTLY:
• Take FIRST THING IN THE MORNING on an empty stomach — immediately upon waking
• Swallow the tablet WHOLE with NO MORE THAN 120 mL (half a glass) of PLAIN WATER ONLY
• No juice, tea, coffee, milk, or flavoured water — these reduce absorption significantly
• No crushing, chewing, or splitting the tablet — the SNAC technology requires the tablet to remain intact
• Wait AT LEAST 30 MINUTES before eating, drinking anything other than plain water, or taking any other oral medicines
• This 30-minute fasting window is NON-NEGOTIABLE for adequate drug absorption
• Even a small sip of coffee or juice during this window can reduce Rybelsus exposure by up to 50%

MISSED DOSE:
• Skip the missed dose entirely if you have already eaten or drunk anything other than plain water that morning
• Take the next dose the following morning as usual
• NEVER double up doses

STORAGE:
• Store in original packaging below 30°C, away from moisture and direct sunlight
• Keep the bottle tightly closed between uses
• Keep out of reach of children
• Do not use after the expiry date printed on the label

How it works:

Rybelsus 3mg contains Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist that mimics and amplifies the natural incretin hormone GLP-1, which is released from intestinal L-cells after meals.

KEY MECHANISMS:

1. GLUCOSE-DEPENDENT INSULIN STIMULATION (Pancreatic Beta Cells):
• Activates GLP-1 receptors on pancreatic beta cells → stimulates insulin secretion ONLY when blood glucose is elevated
• This glucose-dependence is a critical safety advantage: minimal risk of hypoglycaemia (low blood sugar) when used alone
• Promotes beta cell proliferation and survival — potentially preserving insulin-secreting capacity over time

2. GLUCAGON SUPPRESSION (Pancreatic Alpha Cells):
• Inhibits inappropriate glucagon secretion after meals in a glucose-dependent manner
• Reduces hepatic glucose production (gluconeogenesis and glycogenolysis) — lowers fasting blood glucose

3. GASTRIC EMPTYING DELAY:
• Slows gastric emptying, reducing the rate of glucose absorption after meals
• Attenuates postprandial glucose (PPG) spikes — particularly important for T2DM management
• This effect diminishes with prolonged use (tachyphylaxis), with the pancreatic and hepatic effects remaining dominant

4. CENTRAL APPETITE SUPPRESSION (Hypothalamus):
• Crosses the blood-brain barrier; activates GLP-1 receptors in hypothalamic appetite centres
• Reduces hunger, caloric intake, and body weight — independent of glycaemic effect
• Contributes to the 2–4 kg average weight loss observed with Rybelsus 7mg/14mg in PIONEER trials

ORAL DELIVERY TECHNOLOGY — SALCAPROZATE SODIUM (SNAC):
• Semaglutide is normally degraded by gastric proteases and poorly absorbed orally
• Rybelsus uses SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) as an absorption enhancer
• SNAC buffers the local gastric pH around the tablet, protects semaglutide from enzymatic degradation, and transiently enhances its transcellular absorption through the gastric mucosa
• Oral bioavailability: ~1% (compared to near-100% for injectable semaglutide) — hence high drug load and strict fasting administration requirement

Faq for medicine:

1. What is Rybelsus 3mg Tablet used for?
Rybelsus 3mg (Semaglutide 3mg) is an oral GLP-1 receptor agonist used as the starting dose for adults with Type 2 Diabetes to improve glycaemic tolerability before stepping up to the therapeutic 7mg dose. It is taken once daily on an empty stomach under diabetologist guidance.

2. How does Rybelsus Semaglutide 3mg Tablet work?
Semaglutide activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways. The result is lower fasting and postprandial blood glucose, and meaningful body weight reduction at therapeutic 7mg and 14mg doses.

3. How should I take Rybelsus 3mg Tablet correctly?
Take ONE Rybelsus 3mg tablet FIRST THING in the morning on an empty stomach with maximum 120 mL plain water only. Wait at least 30 minutes before eating, drinking anything else, or taking any other oral medicines. Never crush, chew, or split the tablet. Follow your diabetologist's step-up schedule.

4. What are the side effects of Rybelsus Semaglutide 3mg Tablet?
Most common: nausea, vomiting, diarrhoea, reduced appetite — typically at initiation and resolving over weeks. Serious but rare: acute pancreatitis (severe abdominal pain — stop immediately and seek emergency care), hypoglycaemia (when combined with insulin or sulfonylureas), and diabetic retinopathy worsening.

5. Can I buy Rybelsus 3mg Tablet online at the best price in India?
Yes. Buy Rybelsus 3mg (Semaglutide 3mg, Novo Nordisk) online from Shabbir Medical Hall at 10% OFF MRP (Rs 2,674.69 vs Rs 2,971.88 per pack of 10 tablets). Valid diabetologist or endocrinologist prescription required. Fast delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai.

Medicine interaction:

DRUG INTERACTIONS:

1. HYPOGLYCAEMIA RISK — ADDITIVE WITH:
• Sulfonylureas (glibenclamide, glipizide, glimepiride, gliclazide): increased hypoglycaemia risk — consider reducing sulfonylurea dose when initiating Rybelsus
• Insulin: significant hypoglycaemia risk — consider insulin dose reduction and increase glucose monitoring frequency
• Meglitinides (repaglinide, nateglinide): additive hypoglycaemia risk

2. ORAL DRUG ABSORPTION — GASTRIC EMPTYING DELAY EFFECT:
• Rybelsus delays gastric emptying, potentially affecting absorption of other oral medications
• Cyclosporin: increased exposure with semaglutide — monitor closely and take cyclosporin at least 30 minutes before Rybelsus or separate administration as directed
• Oral contraceptives: no clinically significant interaction noted in trials, but take at least 30 minutes after Rybelsus
• Warfarin/other anticoagulants: altered absorption rate possible — monitor INR more closely when starting or stopping Rybelsus
• Thyroxine (levothyroxine): some patients may need TSH monitoring as absorption could be affected

3. ADMINISTRATION INTERACTION:
• ALL other oral medicines should be taken at least 30 minutes AFTER Rybelsus to avoid impaired absorption due to the SNAC-mediated gastric pH buffering effect

SUPPLEMENT INTERACTIONS:
• No established serious supplement interactions
• Alpha-lipoic acid, berberine, chromium supplements: mild blood glucose-lowering properties; monitor glucose more closely

Available Substitutes

WEGOVY 2 4MG INJ

NOVO NORDISK PHARMA INDIA LTD

RS 21950.20 RS 24389.10

10% OFF